PL
PL

We care for the health

of tens of millions of Poles.

News

Diagnostyka Group operates in the medical diagnostics sector in Poland. The Group began its operations in 1998, building a market-leading position in terms of the number of laboratories and blood collection points, the total number of tests performed, the number of employed specialists, and the size of its own courier network. The Group’s business model is based on providing comprehensive medical diagnostic services.

The Group operates on a large and rapidly growing Polish diagnostics market, whose expansion is driven by numerous favorable structural trends. The most important of these include rising wages and increase in the wealth of society, a growing average life expectancy and the aging of the population, increasing health awareness, the rising importance of preventive care, a growing number of chronic diseases, as well as significant growth potential related to the opportunity to bring diagnostic service prices closer to the levels observed in Western European countries.

Diagnostyka performs medical diagnostic tests in the following areas: laboratory diagnostics, genetic diagnostics, histopathological diagnostics, medical imaging diagnostics, comprehensive diagnostics (Longevity+)

The Group’s offer is addressed to the following customer groups:

-individual clients (B2C) – individuals who order and pay for tests at collection points, facilities, or online

-institutional clients (B2B) – small, medium, and large medical entities (both public and private) and other entities, including those from related industries.

Multidimensional growth strategy with limited risk

The Group is expanding through a synergy of organic growth (including volume and pricing), selective acquisitions and disciplined financial management.

The Group’s priorities are to increase its market share in diagnostic imaging, expand and optimise its laboratory network and explore new sales channels, including Longevity+, an innovative subscription model offering a wide range of preventive medicine services.

Multidimensional growth strategy with limited risk

The Group is expanding through a synergy of organic growth (including volume and pricing), selective acquisitions and disciplined financial management.

The Group’s priorities are to increase its market share in diagnostic imaging, expand and optimise its laboratory network and explore new sales channels, including Longevity+, an innovative subscription model offering a wide range of preventive medicine services.

Diagnostyka Group strives for profitable growth, guided by strategic priorities:

  1. 1

    Organic growth

    Supported by market growth, based on increasing volumes and prices
  2. 2

    Optimisation of laboratory and sample collection facility networks

    Economies of scale and improved cost efficiencies through rationalisation of sample collection facility networks and centralisation of laboratory and courier networks
  3. 3

    Strengthening central functions

    Development of central functions, back office and advanced IT and AI solutions
  4. 4

    Further expansion in the diagnostic imaging market

    Selective investment in M&A and organic growth
  5. 5

    Longevity

    Expansion into the area of preventive health¬ care, using the existing customer base and infrastructure

Current reports

All years strzałka w górę
  • All years
  • 2025
Information on Offering costs incurred by the Company
Current reports : Current Report No. 20/2025
Date : 02.06.2025
Hour : 08:29

Date: 19 May 2025

Legal basis: Art. 56.1.2 of the Public Offering Act – Current and periodic information

Subject: Information on Offering costs incurred by the Company
Further to Current Report No. 3/2025 of 6 February 2025, the Management Board of Diagnostyka S.A. (the “Company”) announces that the costs included in the costs of the public offering of 16,147,124 Company shares (the “Offering”) totalled PLN 3.41 million (the “Total Offering Costs”). The calculation includes costs incurred by the Company. In addition to these, a significant portion of the costs was paid by the shareholder selling shares in the IPO, i.e. LX Beta s.a.r.l.

Unless defined otherwise herein, all capitalised terms used in this Current Report have the meanings assigned to them in the Company’s Prospectus approved by the Financial Supervision Authority on 21 January 2025 (the “Prospectus”).

The Total Offering Costs included:

  • costs of preparing and executing the Offering: PLN 2.20 million,
  • underwriting fees – not applicable,
  • cost of drafting the Prospectus, including advisory services: PLN 0.68 million,
  • advertising costs: PLN 0.53 million.

Method applied to account for the Total Offering Costs in the Company’s accounting books: the Offering costs have been included in the costs of 2024 and 2025.

Method applied to disclose the Total Offering Costs in the Company’s financial statements: the costs have been charged against the net profit (loss) for 2024 and 2025.

Average Offering cost per Offer Share: PLN 0.21.

Legal basis:

Section 16.1.12 and 16.1.13 of the Minister of Finance’s Regulation on current and periodic information to be published by issuers of securities and conditions for recognition as equivalent of information whose disclosure is required under the laws of a non-member state of 29 March 2018

For the Company:
Paweł Chytła – Vice President of the Management Board
Dariusz Zowczak – Vice President of the Management Board

Notice of the Annual General Meeting of Diagnostyka S.A.
Current reports : Current Report No. 19/2025
Date : 30.04.2025
Hour : 08:57

Date: 30 April 2025

Subject: Notice of the Annual General Meeting of Diagnostyka S.A.

Legal basis: Art. 56.1.2 of the Public Offering Act – Current and periodic information

Pursuant to Art. 399.1 of the Commercial Companies Code, the Management Board of Diagnostyka S.A. has resolved to convene the Annual General Meeting of the Company, to be held at the Cogiteon Małopolska Science Centre, ul. Stefana Steca 1, Kraków, at 12.00 a.m. on 28 May 2025.

The following agenda has been proposed for the General Meeting:

 

  1. Opening of the Annual General Meeting.
  2. Appointment of the Chair of the Annual General Meeting.
  3. Confirmation that the Annual General Meeting has been duly convened and has the capacity to pass resolutions.
  4. Adoption of the agenda.
  5. Consideration of the reports prepared by the Company’s governing bodies, the financial statements of the Company and the consolidated financial statements of the Group for 2024.
  6. Voting on a resolution to approve the financial statements of the Company for 2024.
  7. Voting on a resolution to approve the consolidated financial statements of the Diagnostyka Group for 2024.
  8. Voting on a resolution to approve the Directors’ Report on the operations of the Diagnostyka Group for the financial year 2024 (including the report on the operations of the Company in that period and sustainable reporting of the Diagnostyka Group for the financial year 2024).
  9. Voting on a resolution on the allocation of the Company’s profit for 2024.
  10. Voting on a resolution to grant discharge from liability to Jakub Swadźba for his activities as President of the Management Board in the period from 1 January to 31 December 2024.
  11. Voting on a resolution to grant discharge from liability to Dariusz Zowczak for his activities as Vice President of the Management Board in the period from 1 January to 31 December 2024.
  12. Voting on a resolution to grant discharge from liability to Marta Rogalska-Kupiec for her activities as Vice President of the Management Board in the period from 1 January to 31 December 2024.
  13. Voting on a resolution to grant discharge from liability to Paweł Chytła for his activities as Vice President of the Management Board in the period from 1 January to 31 December 2024.
  14. Voting on a resolution to grant discharge from liability to Michał Kantor for his activities as Vice President of the Management Board in the period from 1 January to 19 May 2024.
  15. Voting on a resolution to grant discharge from liability to Artur Olender for his activities as Chair of the Supervisory Board in the period from 1 January to 31 December 2024.
  16. Voting on a resolution to grant discharge from liability to Jacek Prusek for his activities as Member of the Supervisory Board in the period from 1 January to 31 December 2024.
  17. Voting on a resolution to grant discharge from liability to Grzegorz Głownia for his activities as Member of the Supervisory Board in the period from 1 January to 31 December 2024.
  18. Voting on a resolution to grant discharge from liability to Marcin Fryda for his activities as Member of the Supervisory Board in the period from 1 January to 31 December 2024.
  19. Voting on a resolution to grant discharge from liability to Paweł Malicki for his activities as Member of the Supervisory Board in the period from 1 January to 31 December 2024.
  20. Voting on a resolution to grant discharge from liability to Matthew Strassberg for his activities as Member of the Supervisory Board in the period from 1 January to 31 December 2024.
  21. Voting on a resolution to grant discharge from liability to Aniela Hejnowska for her activities as Member of the Supervisory Board in the period from 1 October to 31 December 2024.
  22. Voting on a resolution to approve the annual report of the Company’s Supervisory Board for 2024.
  23. Voting on a resolution to grant discharge from liability to Anna Pietrykowska for her activities as President of the Management Board of VITALABO – Laboratoria Medyczne Sp. z o.o. (acquired by the Company on 29 March 2024) in the period from 1 January to 29 March 2024.
  24. Voting on a resolution to grant discharge from liability to Joanna Brąszkiewicz for her activities as Vice President of the Management Board of VITALABO – Laboratoria Medyczne Sp. z o.o. (acquired by the Company on 29 March 2024) in the period from 1 January to 29 March 2024.
  25. Voting on a resolution to grant discharge from liability to Patryk Preis for his activities as Vice President of the Management Board of VITALABO – Laboratoria Medyczne Sp. z o.o. (acquired by the Company on 29 March 2024) in the period from 1 January to 29 March 2024.
  26. Voting on a resolution to grant discharge from liability to Andrzej Drobny for his activities as Vice President of the Management Board of VITALABO – Laboratoria Medyczne Sp. z o.o. (acquired by the Company on 29 March 2024) in the period from 1 January to 29 March 2024.
  27. Voting on a resolution to grant discharge from liability to Jakub Strzelczyk for his activities as President of the Management Board of Platforma Badań Genetycznych Sp. z o.o. (acquired by the Company on 29 November 2024) in the period from 1 January to 8 April 2024.
  28. Voting on a resolution to grant discharge from liability to Przemysław Kulas for his activities as Vice President of the Management Board of Platforma Badań Genetycznych Sp. z o.o. (acquired by the Company on 29 November 2024) in the period from 1 January to 29 November 2024.
  29. Voting on a resolution to grant discharge from liability to Marek Kubicki for his activities as Vice President of the Management Board of Platforma Badań Genetycznych Sp. z o.o. (acquired by the Company on 29 November 2024) in the period from 1 January to 29 November 2024.
  30. Closing of the meeting.

 

Attached to this Report is the notice of the Annual General Meeting, made pursuant to Art. 402.2 of the Commercial Companies Code, along with the draft resolutions of the General Meeting to be voted on and resolutions of the Supervisory Board to be discussed at the General Meeting. Other documents are available in the ‘Periodic reports’ section on the Company’s website at www.grupadiagnostyka.pl/dla-inwestorow/.

 

Legal basis: Section 19.1.1 and 19.1.2 of the Minister of Finance’s Regulation on current and periodic information to be published by issuers of securities and conditions for recognition as equivalent of information whose disclosure is required under the laws of a non-member state, dated 29 March 2018.

 

Signatures of authorised representatives:

Jakub Swadźba – President of the Management Board

Paweł Chytła – Vice President of the Management Board

Appointment of Supervisory Board members
Current reports : Current Report No. 18/2025
Date : 28.04.2025
Hour : 08:56

Date: 28 April 2025

Subject: Appointment of Supervisory Board members

Legal basis: Art. 56.1.2 of the Public Offering Act – Current and periodic information

The Management Board of Diagnostyka S.A. of Warsaw (the “Company”) announces that:

  1. 28 April 2025 was the effective date of Paweł Malicki’s and Matthew Strassberg’s resignation as Members of the Company’s Supervisory Board of the current term of office. According to their representations, their resignation was to take effect on the day of the next General Meeting, which took place on 28 April 2025.
  2. On 28 April 2025, in connection with Paweł Malicki’s and Matthew Strassberg’s resignation, the Extraordinary General Meeting resolved to appoint the following persons as Members of the Company’s Supervisory Board of the current term of office with effect from 28 April 2025:
  • Patrycja Swadźba,
  • Paweł Leżański,
  • Piotr Solorz.

Each of those persons represented to the Company that:

  • they are not entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register of 20 August 1997 (consolidated text: Dz.U. of 2024, No. 979);
  • they are not partners in any partnership under civil law or another type of partnership, or members of a governing body of an incorporated company or any other legal entity, competing with the Company.

The professional biographies and representations of the persons appointed as Members of the Company’s Supervisory Board of the new term of office are attached to this report.

Signatures of authorised representatives:
Jakub Swadźba – President of the Management Board
Paweł Chytła – Vice President of the Management Board

Resolutions passed by Extraordinary General Meeting of the Company
Current reports : Current Report No. 17/2025
Date : 28.04.2025
Hour : 08:55

Date: 28 April 2025

Subject: Resolutions passed by Extraordinary General Meeting of the Company

Legal basis: Art. 56.1.2 of the Public Offering Act – Current and periodic information

The Management Board of Diagnostyka S.A. of Kraków (the “Company”) publishes, attached hereto, the resolutions passed by the Company’s Extraordinary General Meeting held on 28 April 2025, together with the results of voting on each resolution.

Signatures of authorised representatives:
Jakub Swadźba – President of the Management Board
Paweł Chytła – Vice President of the Management Board

Shareholders holding 5% or more of voting rights at Extraordinary General Meeting on 28 April 2025
Current reports : Current Report No. 16/2025
Date : 28.04.2025
Hour : 08:52

Date: 28 April 2025

Subject: Shareholders holding 5% or more of voting rights at Extraordinary General Meeting on 28 April 2025

Legal basis: Art. 70.3 of the Public Offering Act – Shareholders holding 5% or more of total voting rights at General Meeting

The Management Board of Diagnostyka S.A. of Kraków (the “Company”) announces that the following shareholders held 5% or more of total voting rights at the Company’s Extraordinary General Meeting held on 28 April 2025:

  • Jakub Swadźba, holding voting rights attached to 3,186,189 shares, which carry a total of 6,372,378 votes, representing approximately 15.45% of total voting rights at the Extraordinary General Meeting and 12.82% of total voting rights in the Company;
  • ACER CAPITAL PARTNERS SCSP, holding voting rights attached to 6,372,278 shares, which carry a total of 12,744,556 votes, representing approximately 30.90% of total voting rights at the Extraordinary General Meeting and 25.65% of total voting rights in the Company;
  • ACACIA CAPITAL PARTNERS SCSP, holding voting rights attached to 6,372,278 shares, which carry a total of 12,744,556 votes, representing approximately 30.90% of total voting rights at the Extraordinary General Meeting and 25.65% of total voting rights in the Company;

Signatures of authorised representatives:
Jakub Swadźba – President of the Management Board
Paweł Chytła – Vice President of the Management Board

Periodic reports

All years strzałka w górę
  • All years
  • 2025
Quarterly Report of Diagnostyka Group for the 1Q of 2025
Consolidated annual report of Diagnostyka Group for 2024
Annual Diagnostyka presentation for 2024
Financial Results of the Diagnostyka Group 2024

Good Practices of Companies Listed on the GPW (DPSN)

Reports
Update with future reports.

Financial results

Download data in XLS format

Shareholding structure

Update for future transa strzałka w górę
  • Update for future transa
  • Dividend policy
  • Stock quotes
Update for future transa Dividend policy Stock quotes

Update for future transa

Shareholder Number of shares (%) of shares (%) of votes
Grzegorz Głownia 1) 6,372,379 18.88 25.65
Jacek Prusek 2) 6,372,379 18.88 25.65
Jakub Swadźba 3,186,189 9.44 12.82
Others 17,825,553 52,81 35,88
Total 33,756,500 100 100

1) Directly and through ACER Capital Partners SCSp

2) Directly and through ACACIA Capital Partners SCSp

 

Dividend policy

In future years, the Management Board intends to recommend the payment of dividends to shareholders for the financial year. Subject to market conditions and the factors set out below, the Management Board intends to recommend to the General Meeting that a dividend of the Company’s 50% net profit attributable to Shareholders of the Parent Company, with the possibility of an increase in years of exceptionally strong financial performance, as assessed by the Management Board.

In making its recommendation, the Management Board will take into account:

  • restrictions of a business nature (in particular restrictions on dividend payments contained in the Group’s financing agreements) and restrictions of a legal nature affecting the amount of dividend payments that may be paid to shareholders,
  • the Group’s financial standing (in the context of extraordinary economic circumstances or significant capital needs),
  • the Group’s strategy and development plans.

The Management Board does not guarantee the amount of profit achieved by the Company in the future or the portion of it that can be allocated to the payment of dividends. The decision to pay dividends and the amount of dividend payments to be paid is in any case at the discretion of the shareholders in the General Meeting, the shareholders being in no way bound by the recommendation of the Management Board.

Stock quotes

Monitoruj wszystkie rynki na TradingView

Company Authorities

Our Management Board

  • Jakub Swadźba

    Jakub Swadźba

    President of the Management Board

  • Dariusz Zowczak

    Dariusz Zowczak

    Vice-President of the Management Board

  • Marta Rogalska-Kupiec

    Marta Rogalska-Kupiec

    Vice-President of the Management Board

  • Paweł Chytła

    Paweł Chytła

    Vice-President of the Management Board

  • Jaromir Pelczarski

    Jaromir Pelczarski

    Vice-President of the Management Board

Supervisory Board

  • Artur Olender

    Chairman of the Supervisory Board

  • Jacek Prusek

    Member of the Supervisory Board

  • Grzegorz Głownia

    Member of the Supervisory Board

  • Marcin Fryda

    Member of the Supervisory Board

  • Patrycja Swadźba

    Member of the Supervisory Board

  • Paweł Leżański

    Member of the Supervisory Board

  • Piotr Solorz

    Member of the Supervisory Board

  • Aniela Hejnowska

    Member of the Supervisory Board

Historical background

The Group’s history is marked by the following milestones:

  1. 1998

    Establishment of Diagnostyka s.c. in Kraków and opening of the first laboratory

  2. 2000

    Establishment of Diagnostyka Gorzów Wielkopolski and takeover of Medica Zielona Góra

  3. 2001

    Establishment of Diagnostyka Warszawa and merger with Diagnostyka Kraków

  4. 2004

    Implementation of the management system and ISO 9001 certification

  5. 2006

    Opening of a branch in Wrocław and own molecular biology laboratory in Kraków

  6. 2008

    Dynamic development of the Group’s activities through the creation and acquisition of new entities, including: ODM Kielce, Diagnostyka Częstochowa, Loma Opole, Top-Lab Lublin

  7. 2010

    Obtaining ISO/IEC 17025 accreditation confirming the competence of testing laboratories

  8. 2011

    Acquisition of a separate organised part of the company and acquisition of the “Dr n. med. Teresa Fryda Laboratorium Medyczne”

  9. 2011

    Securing the financial investor MID Europa Partners and merger with a company owned by Marcin Fryda, who becomes a shareholder of the Company

  10. 2011

    Obtaining ISO 15189 accreditation confirming the competence of medical diagnostic laboratories

  11. 2012

    Acquisition of Medis and Alpha Medical — ensuring the presence of Diagnostyka in every voivodeship in Poland

  12. 2013

    Acquisition of Olympus Consilio (now Diagnostyka Consilio) based in Łódź, which initiated the Group’s entry into the market for histopathology diagnostic services

  13. 2014

    Opening of the new Diagnostyka headquarters in Kraków and the largest Central Network Laboratory in Poland (and one of the most advanced in the world)

  14. 2016

    Implementation of an information security system and obtaining ISO/IEC 27001 certification

  15. 2016

    Acquisition of the majority of shares in Oncogene Diagnostics sp. z o.o.

  16. 2017

    Launch of the Group’s e-commerce platform

  17. 2017

    Implementation of an environmental system and obtaining ISO 14001 certification

  18. 2018

    Acquisition of one of the largest and most advanced genetic laboratories — Genesis Medical Genetics Centres from Poznań

  19. 2018

    Acquisition of Vitalabo Laboratoria Medyczne sp. z o.o. with a well-established position on the laboratory market in northern Poland having, at the time of acquisition, three central laboratories and approximately 100 sample collection facilities

  20. 2018

    The establishment of Diagnostyka Consilio sp. z o.o. Poznań sp.k. and acquisition of new histopathology specialists, thereby increasing market share in the histopathology services market in Wielkopolskie Voivodship

  21. 2018

    Expanding the possibility of safe blood collection at the patient’s home, thanks to cooperation with the uPacjenta.pl platform

  22. 2019

    Acquisition of the Histamed histopathology laboratory in Gliwice (now Histamed DC sp. z o.o.)

  23. 2020

    Group’s involvement in the fight against the coronavirus pandemic — performing free SARS-CoV-2 testing for medics and teachers and performing 10% of all COVID-19 tests performed in Poland

  24. 2021

    Acquisition of one of Poland’s largest e-commerce sites dedicated to diagnostic tests — ZdroweGeny.pl

  25. 2021

    Group’s investment in a start-up for doctors — Badania.pl

  26. 2021

    Opening of a central laboratory in Warsaw equipped with the most advanced laboratory technology in Europe

  27. 2021

    Transformation into a joint stock company

  28. 2021

    Publication of the first ESG report

  29. 2022

    Involvement of the Group in providing in-kind and financial assistance to victims of the conflict in Ukraine and offering free examinations to refugees

  30. 2023

    Acquisition of the company NZOZ Diagno-Med. sp. z o.o. strengthening the Group’s position in the market of the Śląskie Voivodeship.

  31. 2023

    Commencement of the Group’s activities in the area of diagnostic imaging — acquisition of the company Zakład Rentgen i USG Wyrobek

  32. 2023

    25th anniversary of the Diagnostyka Group. Rebranding and refreshment of the company’s visual identity.

  33. 2024

    Acquisition of the company Telediagnostyka sp. z o.o. and the company Livmed sp. z o.o. continuing the Group’s expansion in the diagnostic imaging market

  34. 2025

    Initial Public Offering of shares in Diagnostyka S.A. and debut on the Warsaw Stock Exchange
Poprzedni
Następny

Investor calendar

  • Separate and consolidated half-year reports for the first half of 2025

  • Separate and consolidated quarterly reports for the third quarter of 2025

Upcoming events

Contact

Downloads

Link to an IPO page

Go